专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP0524781A1 Therapeutic amides 失效
标题翻译：治疗酰胺。
公开(公告)号：EP0524781A1
公开(公告)日：1993-01-27
申请号：EP92306588.2
申请日：1992-07-17
申请人： ZENECA LIMITED
发明人： Russell, Keith , Ohnmacht, Cyrus John , Gibson, Keith Hopkinson
IPC分类号： C07D213/75 , C07D213/70 , C07D213/50 , C07D239/38 , C07D241/18 , C07D277/36 , C07D333/34 , C07C235/16 , C07C317/40 , A61K31/38 , A61K31/425 , A61K31/44 , A61K31/505 , A61K31/50 , A61K31/165
CPC分类号： C07D213/70 , C07C235/16 , C07C317/40 , C07C317/44 , C07C317/50 , C07C2601/08 , C07D213/50 , C07D213/75 , C07D239/38 , C07D241/18 , C07D277/36 , C07D333/34
摘要： Amides having formula I:-

wherein E, X, R² and R³ have the meanings given in the specification, and pharmaceutically acceptable salts and pharmaceutically acceptable in vivo hydrolysable esters thereof,
which are useful in the treatment of urinary incontinence. Further provided are processes for preparing the amides and pharmaceutical compositions containing them.
摘要翻译：具有式I的酰胺： - 其中E，X，R 2和R 3具有说明书中给出的含义及其药学上可接受的盐和药学上可接受的体内可水解的酯，其可用于治疗的尿失禁。还提供了制备含有它们的酰胺和药物组合物的方法。

2. 发明授权

EP0482771B1 Heterocyclic acids 失效
标题翻译：杂环酸
公开(公告)号：EP0482771B1
公开(公告)日：1997-06-18
申请号：EP91308805.0
申请日：1991-09-26
申请人： ZENECA LIMITED
发明人： Faull, Alan Wellington , Russell, Keith , Watkins, William John
IPC分类号： C07D417/04 , C07D405/04 , A61K31/415 , A61K31/425 , C07D263/26
CPC分类号： C07D403/04 , C07D263/26 , C07D417/04

3. 发明公开

EP0482771A2 Heterocyclic acids 失效
标题翻译： HeterozyklischeSäuren。
公开(公告)号：EP0482771A2
公开(公告)日：1992-04-29
申请号：EP91308805.0
申请日：1991-09-26
申请人： ZENECA LIMITED
发明人： Faull, Alan Wellington , Russell, Keith , Watkins, William John
IPC分类号： C07D417/04 , C07D405/04 , A61K31/415 , A61K31/425 , C07D263/26
CPC分类号： C07D403/04 , C07D263/26 , C07D417/04
摘要： The invention concerns novel 1,3-dioxane alkenoic acid derivatives of the formula I

wherein : n is the integer 1 or 2 ;

Y is methyleneoxy, vinylene or ethylene ;
A 1 is (1-6C)alkylene ;
R 1 is a group of the formula R 2 .A 2 -, in which :
R 2 is phenyl unsubstituted or bearing up to three substituents which are independently selected from (1-6C)alkyl, (1-6C)alkoxy, (2-6C)alkanoyl (1-6C)alkylthio, (1-6C)alkylsulphonyl, halogeno, trifluoromethyl, nitro and cyano ;
A 2 is a direct bond to R 2 or a group of the formula -W-C(R 4 )(R 5 )-wherein W is oxygen, methylene or a direct bond to R 2 , and R 4 and R 5 are independently (1-4C)alkyl ;
Q is a heterocyclyl group selected from thiazol-5-yl and imidazol-5-yl, the latter being unsubstituted or bearing a (1-12C)alkyl group at the 1-position of the imidazole ring ; and
R 3 is hydroxy, a physiologically acceptable alcohol residue, or (1-4C)alkanesulphonamido ;

or a pharmaceutically acceptable salt thereof. The compounds are thromboxane A 2 antagonists and inhibitors of thromboxane A 2 synthase, and are useful on the treatment of a variety of diseases in which thromboxane A 2 is involved, such as is ischaemic heart disease, cerebrovascular disease and peripheral vascular disease. The invention also includes processes for the manufacture and use of the compounds, and pharmaceutical compositions containing them.
摘要翻译：本发明涉及式I 的新型1,3-二恶烷烯酸衍生物，其中：n为整数1或2; Y是亚甲氧基，亚乙烯基或亚乙基; A 1是（1-6C）亚烷基; R 1是式R 2的基团.A 2 - ，其中：R 2是未取代的或具有至多三个独立地选自（1-6C）烷基的取代基的苯基，（ 1-6C）烷氧基，（2-6C）烷酰基（1-6C）烷硫基，（1-6C）烷基磺酰基，卤代，三氟甲基，硝基和氰基; A 2与R 2或式-WC（R 4）（R 5） - 的基团直接键合，其中W是氧，亚甲基或与R 2的直接键合，和R 4和R 5独立地是（1-4C）烷基; Q是选自噻唑-5-基和咪唑-5-基的杂环基，后者是未取代的或在咪唑环的1位带有（1-12C）烷基; R 3为羟基，生理上可接受的醇残基或（1-4C）烷基磺酰氨基; 或其药学上可接受的盐。化合物是凝血恶烷A2拮抗剂和凝血恶烷A2合酶抑制剂，可用于治疗其中涉及血栓素A2的各种疾病，例如缺血性心脏病，脑血管病和外周血管疾病。本发明还包括制备和使用化合物的方法以及含有它们的药物组合物。

4. 发明授权

EP0524781B1 Therapeutic amides 失效
标题翻译：治疗酰胺
公开(公告)号：EP0524781B1
公开(公告)日：1996-03-27
申请号：EP92306588.2
申请日：1992-07-17
申请人： ZENECA LIMITED
发明人： Russell, Keith , Ohnmacht, Cyrus John , Gibson, Keith Hopkinson
IPC分类号： C07D213/75 , C07D213/70 , C07D213/50 , C07D239/38 , C07D241/18 , C07D277/36 , C07D333/34 , C07C235/16 , C07C317/40 , A61K31/38 , A61K31/425 , A61K31/44 , A61K31/505 , A61K31/50 , A61K31/165
CPC分类号： C07D213/70 , C07C235/16 , C07C317/40 , C07C317/44 , C07C317/50 , C07C2601/08 , C07D213/50 , C07D213/75 , C07D239/38 , C07D241/18 , C07D277/36 , C07D333/34

5. 发明公开

EP0482771A3 Heterocyclic acids 失效
标题翻译：杂环酸
公开(公告)号：EP0482771A3
公开(公告)日：1992-07-01
申请号：EP91308805.0
申请日：1991-09-26
申请人： ZENECA LIMITED
发明人： Faull, Alan Wellington , Russell, Keith , Watkins, William John
IPC分类号： C07D417/04 , C07D405/04 , A61K31/415 , A61K31/425 , C07D263/26
CPC分类号： C07D403/04 , C07D263/26 , C07D417/04
摘要： The invention concerns novel 1,3-dioxane alkenoic acid derivatives of the formula I

wherein : n is the integer 1 or 2 ;
Y is methyleneoxy, vinylene or ethylene ; A 1 is (1-6C)alkylene ; R 1 is a group of the formula R 2 .A 2 -, in which : R 2 is phenyl unsubstituted or bearing up to three substituents which are independently selected from (1-6C)alkyl, (1-6C)alkoxy, (2-6C)alkanoyl (1-6C)alkylthio, (1-6C)alkylsulphonyl, halogeno, trifluoromethyl, nitro and cyano ; A 2 is a direct bond to R 2 or a group of the formula -W-C(R 4 )(R 5 )-wherein W is oxygen, methylene or a direct bond to R 2 , and R 4 and R 5 are independently (1-4C)alkyl ; Q is a heterocyclyl group selected from thiazol-5-yl and imidazol-5-yl, the latter being unsubstituted or bearing a (1-12C)alkyl group at the 1-position of the imidazole ring ; and R 3 is hydroxy, a physiologically acceptable alcohol residue, or (1-4C)alkanesulphonamido ;
or a pharmaceutically acceptable salt thereof. The compounds are thromboxane A 2 antagonists and inhibitors of thromboxane A 2 synthase, and are useful on the treatment of a variety of diseases in which thromboxane A 2 is involved, such as is ischaemic heart disease, cerebrovascular disease and peripheral vascular disease. The invention also includes processes for the manufacture and use of the compounds, and pharmaceutical compositions containing them.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式